CHICAGO--(BUSINESS WIRE)--Radiation Therapy Oncology Group (RTOG) investigators and ImClone Systems Incorporated (Nasdaq: IMCL) today announced that adding the biologic agent cetuximab (ERBITUX®) to chemotherapy and radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) resulted in higher median survival rates and two-year overall survival rates than previous RTOG studies in patients with Stage III A/B inoperable NSCLC. Investigators for RTOG, an NCI-funded national cooperative clinical trials group and clinical research enterprise component of the American College of Radiology (ACR), presented their results today at the American Society of Clinical Oncology’s 44th Annual Meeting in Chicago.
